21 – 40 of 147
- show: 20
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2023
-
Mark
Dopamine agonist serum concentrations and impulse control disorders in Parkinson's disease
2023) In European Journal of Neurology(
- Contribution to journal › Article
-
Mark
Healthcare resource utilization and device-aided therapy discussions with eligible patients across the Parkinson's disease continuum : Revelations from the MANAGE-PD validation cohort
(
- Contribution to journal › Article
-
Mark
Levodopa Dose Equivalency in Parkinson's Disease : Updated Systematic Review and Proposals
(
- Contribution to journal › Article
- 2022
-
Mark
Diagnostic work up : Laboratory and biomarkers
(
- Chapter in Book/Report/Conference proceeding › Book chapter
-
Mark
Caregiver Burden and Quality of Life in Late Stage Parkinson’s Disease
(
- Contribution to journal › Article
-
Mark
Non-dopaminergic approaches to the treatment of motor complications in Parkinson's disease
(
- Contribution to journal › Scientific review
-
Mark
Gait and balance among people with de novo vs. mild to moderate Parkinson’s disease
2022) 6th International Conference on Neurology and Brain Disorders (Virtual)(
- Contribution to conference › Abstract
-
Mark
Quality of life and resource utilization-Swedish data from the Care of Late-Stage Parkinsonism (CLaSP) study
(
- Contribution to journal › Article
-
Mark
Validation of the PD home diary for assessment of motor fluctuations in advanced Parkinson's disease
(
- Contribution to journal › Article
-
Mark
Impact of age at onset on symptom profiles, treatment characteristics and health-related quality of life in Parkinson’s disease
(
- Contribution to journal › Article
-
Mark
Insights on Genetic and Environmental Factors in Parkinson's Disease from a Regional Swedish Case-Control Cohort
(
- Contribution to journal › Article
-
Mark
Safinamide in the treatment pathway of Parkinson’s Disease : a European Delphi Consensus
(
- Contribution to journal › Article
-
Mark
Pharmacokinetics of Intravenously (DIZ101), Subcutaneously (DIZ102), and Intestinally (LCIG) Infused Levodopa in Advanced Parkinson Disease
(
- Contribution to journal › Article
-
Mark
Why do ‘OFF’ periods still occur during continuous drug delivery in Parkinson’s disease?
(
- Contribution to journal › Scientific review
-
Mark
Caregiver Burden in Late-Stage Parkinsonism and Its Associations
(
- Contribution to journal › Article
-
Mark
Objective Observer vs. Patient Motor State Assessments Using the PD Home Diary in Advanced Parkinson's Disease
(
- Contribution to journal › Article
-
Mark
High risk of developing dementia in Parkinson’s disease : a Swedish registry-based study
(
- Contribution to journal › Article
-
Mark
Opicapone versus placebo in the treatment of Parkinson’s disease patients with end-of-dose motor fluctuation-associated pain : rationale and design of the randomised, double-blind OCEAN (OpiCapone Effect on motor fluctuations and pAiN) trial
(
- Contribution to journal › Article
-
Mark
Effects of Levodopa-Carbidopa Intestinal Gel on Dyskinesia and Non-Motor Symptoms Including Sleep : Results from a Meta-Analysis with 24-Month Follow-Up
(
- Contribution to journal › Scientific review
-
Mark
Comparative Effectiveness of Device-Aided Therapies on Quality of Life and Off-Time in Advanced Parkinson’s Disease : A Systematic Review and Bayesian Network Meta-analysis
(
- Contribution to journal › Scientific review